Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/87854
Title: P10-drugs for half the world : paediatric clinical pharmacology using Adapt® in paediatric patients : pharmacokinetic modelling for Lamotrigine
Authors: Mifsud, Janet
Soler, D.
Shabbi, H.
Keywords: Pharmacokinetics -- Mathematical models
Pharmacokinetics -- Data processing
Clinical pharmacology
Pediatric pharmacology
Issue Date: 2010
Publisher: John Wiley & Sons, Inc.
Citation: Mifsud, J., Soler, D., & Shabbi, H. (2010). P10-drugs for half the world : paediatric clinical pharmacology using Adapt® in paediatric patients : pharmacokinetic modelling for Lamotrigine. Basic & Clinical Pharmacology & Toxicology, 107(s1), 455-456.
Abstract: It is estimated that around 70 % of medicinal products used in paediatric population have never been specifically evaluated for use in that age group. There is still a lack of models that will allow accurate predictions of drug levels in these populations. This is of particular importance in a chronic neurological condition such as epilepsy. In this study, a sparse data model, using AdaptÒ software was developed for lamotrigine in a group of paediatric patients. Plasma lamotrigine levels in 20 paediatric patients (mean ± S.D., age 8.85 ± 3.47 years and weight, 32.22 ±20.81 kg) were measured. The pharmacokinetic parameters in the four groups (lamotrigine alone, with valproate, with carbamazepine, and with clonazepam) were estimated. The only significant difference (P < 0.05)was obtained between the four groups in the case of estimated volume of distribution, predicated minimum plasma concentration, and area under the curve. [excerpt]
URI: https://www.um.edu.mt/library/oar/handle/123456789/87854
Appears in Collections:Scholarly Works - FacM&SCPT

Files in This Item:
File Description SizeFormat 
P10-Drugs For Half The World Paediatric Clinical Pharmacology Using Adapt®.pdf
  Restricted Access
82.57 kBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.